Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by MetzGERon Oct 18, 2023 5:01pm
112 Views
Post# 35689867

RE:RE:RE:RE:RE:Questions

RE:RE:RE:RE:RE:QuestionsYou got it wrong BellEnd. The Phase IIa of Shiseido wasnt that Good. But they noticed that a lower Dose of cells is much more effektive then a high Dose of cells.
so Shiseido Did a  Phase IIb Trial with lower doses of cells. This results we don't know, Andrew Doesnt know. Only Shiseido knows the results and Are going to hairloss conferences  with that.

the only thing Andrew Said in AGM is that he has some ideas How to increase the results of RCH-01 Without Knowing the Phase IIb Studie results. He is a clever guy and very confident about the product. He never Said that Shiseido failed he only Said How to increase.

i just noticed some People Took These low share prices  to get in. Congratulations. My fault that i bought do high. Wished i could Buy Shares at ~0.10$ .... it is so cheap...
<< Previous
Bullboard Posts
Next >>